Pharmaceuticals

Opposition Practice at the EPO – Advice for Patent Owners

  Opposition proceedings at the EPO provide a time-limited opportunity for a third party to challenge the validity of a granted European patent centrally, with the aim of achieving revocation, or at least a limitation, of the granted patent rights. In this article, we will give an overview of the...

Read more

Patenting Biological Simulations in Drug Discovery

  Our article ‘Patenting Biological Simulations in Drug Discovery’ has been published in Drug Discovery Today, by Elsevier. It examines the challenges faced when pursuing patent protection for biological simulations, particularly in view of the guidance provided by the European Patent Office in G1/19. Article Highlights: Biological simulations typically require...

Read more

Is Dasatinib Dead? – An Incredible Change to the Plausibility Threshold

  It is just over four years since Board 3.3.01 of the EPO Boards of Appeal delivered its much-anticipated decision in the Dasatinib case (T 488/16). Having been closely involved in that case on behalf of one of the opponents, it was obvious to me that the decision represented a...

Read more

Proving Plausibility – Can Post-filed Evidence Support your Patent: Part 2

  As we found in the first part of this two-part series, timing is everything when it comes to filing a patent application. Filing too early may mean your application may lack the essential evidence to support your invention. But can post-filed data resuscitate your chances of a patent? In...

Read more

Proving Plausibility – How a Deficient Disclosure can be Terminal for a Patent: Part 1

  Timing is everything when it comes to filing a patent application. Too early and your application may lack the essential evidence to support your invention. Too late and the competition may beat you to it. But problems may arise if suitable evidence is not included in your patent application,...

Read more